New drug trial offers hope for restoring skin color in vitiligo patients
NCT ID NCT07431177
Summary
This study is testing an experimental drug called GIA632 for adults with non-segmental vitiligo, a condition that causes loss of skin color. Researchers want to find the most effective and safe dose to reduce white patches on the face and body. The trial involves 210 participants and will help determine if the treatment should move to larger final-stage testing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Cahaba Derm and skin hlth ctr 27
RECRUITINGBirmingham, Alabama, 35244, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Miami Derm and Laser Institute
RECRUITINGMiami, Florida, 33173, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Novartis Investigative Site
RECRUITINGSydney, New South Wales, 2010, Australia
-
Novartis Investigative Site
RECRUITINGWaitara, New South Wales, 2077, Australia
-
Novartis Investigative Site
RECRUITINGToronto, Ontario, M3H 5Y8, Canada
-
Revival Research Institute
RECRUITINGTroy, Michigan, 48084, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.